Todd Palmby
Overview
Explore the profile of Todd Palmby including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gong X, Hu M, Liu J, Kim G, Xu J, McKee A, et al.
Nat Commun
. 2022 Jul;
13(1):4349.
PMID: 35896580
Small molecule kinase inhibitors (SMKIs) are being approved at a fast pace under expedited programs for anticancer treatment. In this study, we construct a multi-domain dataset from a total of...
2.
21st Century Cardio-Oncology: Identifying Cardiac Safety Signals in the Era of Personalized Medicine
Sheng C, Amiri-Kordestani L, Palmby T, Force T, Hong C, Wu J, et al.
JACC Basic Transl Sci
. 2017 Jul;
1(5):386-398.
PMID: 28713868
Cardiotoxicity is a well-established complication of oncology therapies. Cardiomyopathy resulting from anthracyclines is a classic example. In the past decade, an explosion of novel cancer therapies, often targeted and more...
3.
Ning Y, Suzman D, Maher V, Zhang L, Tang S, Ricks T, et al.
Oncologist
. 2017 Apr;
22(6):743-749.
PMID: 28424325
Implications For Practice: This accelerated approval of atezolizumab for second-line use in advanced urothelial carcinoma provides patients with an effective, novel treatment option for the management of their disease. This...
4.
Beaver J, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al.
Clin Cancer Res
. 2015 Sep;
21(21):4760-6.
PMID: 26324739
On February 3, 2015, the FDA granted accelerated approval to palbociclib (IBRANCE, Pfizer Inc.), an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), for use in combination with...
5.
Kim G, Ison G, McKee A, Zhang H, Tang S, Gwise T, et al.
Clin Cancer Res
. 2015 Jul;
21(19):4257-61.
PMID: 26187614
On December 19, 2014, the FDA approved olaparib capsules (Lynparza; AstraZeneca) for the treatment of patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been...
6.
Amiri-Kordestani L, Blumenthal G, Xu Q, Zhang L, Tang S, Ha L, et al.
Clin Cancer Res
. 2014 Jun;
20(17):4436-41.
PMID: 24879797
On February 22, 2013, the FDA licensed ado-trastuzumab emtansine (Kadcyla; Genentech, Inc.) for use as a single agent for the treatment of patients with human epidermal growth factor receptor 2...
7.
Kluetz P, Pierce W, Maher V, Zhang H, Tang S, Song P, et al.
Clin Cancer Res
. 2013 Nov;
20(1):9-14.
PMID: 24190979
On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant...
8.
Kluetz P, Ning Y, Maher V, Zhang L, Tang S, Ghosh D, et al.
Clin Cancer Res
. 2013 Oct;
19(24):6650-6.
PMID: 24150234
On December 10, 2012, the U.S. Food and Drug Administration granted full approval for a modified indication for abiraterone acetate (Zytiga tablets; Janssen Biotech, Inc.) in combination with prednisone for...
9.
Ning Y, Pierce W, Maher V, Karuri S, Tang S, Chiu H, et al.
Clin Cancer Res
. 2013 Oct;
19(22):6067-73.
PMID: 24141628
This article summarizes the regulatory evaluation that led to the full approval of enzalutamide (XTANDI, Medivation Inc.) by the U.S. Food and Drug Administration (FDA) on August 31, 2012, for...
10.
Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al.
Clin Cancer Res
. 2013 Mar;
19(9):2289-93.
PMID: 23515405
The data and regulatory considerations leading to the U.S. Food and Drug Administration (FDA) January 30, 2012 approval of Erivedge (vismodegib) capsules for the treatment of patients with recurrent, locally...